Lyell Immunopharma (NASDAQ:LYEL) Insider David Shook Sells 1,977 Shares of Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) insider David Shook sold 1,977 shares of the business’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $12.64, for a total transaction of $24,989.28. Following the completion of the sale, the insider directly owned 20,923 shares of the company’s stock, valued at $264,466.72. This represents a 8.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lyell Immunopharma Stock Up 3.8%

Lyell Immunopharma stock opened at $13.72 on Friday. The company has a market capitalization of $320.14 million, a PE ratio of -0.99 and a beta of -0.09. The firm has a fifty day simple moving average of $19.32 and a two-hundred day simple moving average of $23.33. Lyell Immunopharma, Inc. has a twelve month low of $8.46 and a twelve month high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share for the quarter, hitting the consensus estimate of ($1.10). The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. As a group, equities analysts expect that Lyell Immunopharma, Inc. will post -7.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently modified their holdings of the company. BBR Partners LLC bought a new position in shares of Lyell Immunopharma during the fourth quarter valued at about $210,000. ExodusPoint Capital Management LP bought a new position in shares of Lyell Immunopharma during the fourth quarter valued at about $262,000. Marshall Wace LLP bought a new position in shares of Lyell Immunopharma during the second quarter valued at about $94,000. Jane Street Group LLC purchased a new position in shares of Lyell Immunopharma during the fourth quarter valued at about $382,000. Finally, Barclays PLC increased its position in shares of Lyell Immunopharma by 1,239.5% during the fourth quarter. Barclays PLC now owns 15,967 shares of the company’s stock valued at $491,000 after buying an additional 14,775 shares during the period. 66.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on LYEL shares. Zacks Research raised shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price objective on shares of Lyell Immunopharma in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Lyell Immunopharma in a research note on Tuesday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Lyell Immunopharma in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.00.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.